Sanofi and Translate Bio announced March 12 the start of a phase 1/2 clinical trial for their mRNA COVID-19 vaccine candidate. The study will assess the vaccine candidate’s safety, immune response and reactogenicity with 415 participants across 13 investigational sites. In parallel, preclinical studies are underway to evaluate additional mRNA candidates against emerging SARS-CoV-2 variants.
Two vaccine candidates against COVID-19
Sanofi has joined forces to develop two vaccine candidates to help prevent and control COVID-19
How Sanofi COVID-19 vaccine candidates are designed
Sanofi is taking a two-pronged approach to vaccine development to help meet global public health needs during the coronavirus pandemic.